Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNETO: GD2 CAR T cells in Neuroblastoma
NCT05990751Phase 1Active, not recruiting
- Sponsor
- University College London
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GD2.CAR-TVS-CTL in neuroblastoma, sponsored by University College London. Primary endpoints: Safety of administering the ATIMP at 28 days and Number of therapeutic products generated and infused at 28 days. Started Apr 2024; status: active, not recruiting.
02
Drugs
GD2.CAR-TVS-CTL
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT05990751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05990751.